New
research programme unveiled by Boehringer Ingelheim and the European
Foundation for the Study of Diabetes (EFSD) invites European diabetes
research projects to apply for funding
INGELHEIM, Germany - Thursday, January 17th 2013 [ME NewsWire]
(BUSINESS
WIRE)-- The Boehringer Ingelheim and EFSD diabetes partnership has
opened submissions for diabetes research grant applications from across
Europe. In a collaboration which aims to stimulate and accelerate
European research in diabetes, the EFSD/Boehringer Ingelheim European
Diabetes Research Programmes have dedicated more than 2.5 million euros
over three years to support research projects targeting specific areas
of interest.
“Diabetes affects more than 371 million people
worldwide and diabetes remains undiagnosed in up to 50% of cases,” said
Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer
Ingelheim. “We are delighted to partner with the EFSD on this initiative
and hope the grant encourages and supports new research in the field of
diabetes.”
The joint diabetes grant programme will focus on two
areas of interest in order to achieve the goals and objectives of the
programmes and will welcome proposals which target the following:
1. Regulations of secretion and/or function of non-insulin peptides from the endocrine pancreas. (Basic research)
2. Mechanisms relating renal dysfunction to cardiovascular disease in type 2 diabetes. (Clinical research)
The
EFSD/Boehringer Ingelheim European Diabetes Research Programmes will
consider funding of basic research projects up to 100,000 euros in total
for projects lasting up to 2 years, and clinical research projects up
to 400,000 euros in total for projects up to 3 years in duration.
Funding applications for research projects will be accepted until 1
April 2013.
“The EFSD is proud to collaborate once again with
Boehringer Ingelheim on this important research initiative,” said Dr.
Viktor Joergens, Executive Director and Vice Director, EFSD. “Ensuring
sufficient funding for diabetes research in Europe is vital and we hope
that this partnership leads the way to provide invaluable contributions
to diabetes research.”
Applications are invited from single
non-profit institutions or groups of institutions in Europe and will be
subject to a scientific review by a specialised and independent
committee. The ad hoc committee will review the grant applications on
criteria such as significance, approach and innovation. Researchers who
are interested in applying for a grant can download an application form
from www.EuropeanDiabetesFoundation.org.
The deadline for submissions is 1 April 2013 and the anticipated award date is in June 2013.
~ends~
Please
click on the link below for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/17_january_2013_efsd.html
###
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Arnd Prilipp
Phone: +49 6132 – 77 2091
Email: press@boehringer-ingelheim.com